Phase I Study To Determine The Maximally Tolerated Dose Of Oral, Daily CP-868,596 And CP-868,596 Plus AG-013736 When Given In Combination With Docetaxel Administered Every 3 Weeks To Patients With Advanced Solid Tumors

Trial Profile

Phase I Study To Determine The Maximally Tolerated Dose Of Oral, Daily CP-868,596 And CP-868,596 Plus AG-013736 When Given In Combination With Docetaxel Administered Every 3 Weeks To Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Crenolanib (Primary) ; Axitinib; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AROG Pharmaceuticals; Pfizer
  • Most Recent Events

    • 18 Jan 2012 Company (Arog Pharmaceuticals) added as trial sponsor as reported by ClinicalTrials.gov.
    • 25 Aug 2011 Actual end date changed from Jul 2008 to Jun 2008 as reported by ClinicalTrials.gov.
    • 10 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top